Therapy News and Research

RSS

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

Patients with diabetic nephropathy (kidney disease caused by diabetes) who received high dose B-vitamin therapy experienced a more rapid decline in kidney function and had a higher rate of heart attack and stroke than patients who received placebo, according to a study in the April 28 issue of JAMA.

28 Apr 2010

Study examines world-wide use of HSCT

An examination of the world-wide use of hematopoietic stem cell transplantation, which involves transplantation of blood stem cells derived from the bone marrow or blood, finds that there are significant differences in transplant rates between countries and continental regions by indication and donor type, and that HSCT is most frequently used in countries with higher gross national incomes and governmental health care expenditures, according to a study in the April 28 issue of JAMA.

28 Apr 2010

Causes of death in AIDS patients

New research shows that Antiretroviral Therapy (ART) continues to dramatically reduce rates of mortality from HIV infection in high-income countries, such that non-AIDS-related deaths exceed AIDS deaths after approximately four years of taking ART.

28 Apr 2010

Volcano to distribute AngioSculpt PTCA Scoring Balloon Catheter in Japan

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has entered into a distribution agreement with AngioScore for its AngioSculpt® PTCA Scoring Balloon Catheter for coronary indications in Japan. This is the first of what Volcano believes will be many products distributed by Volcano Japan, which now includes more than 50 direct sales representatives.

28 Apr 2010

Transplanted pig cells may bring relief from insulin injections in type I diabetics

Living Cell Technologies, a New Zealand based biotechnology company that is investigating the use of living pig cells in the treatment of diabetes has now received $700,000 (US$500,000) grant from the Juvenile Diabetes Research Foundation International for further human trials.

28 Apr 2010

Myriad Genetics OnDose collection kit eliminates need for frozen sample handling

Myriad Genetics, Inc. today announced a significant improvement in the sample collection kit for OnDoseTM, its 5-Fluorouracil (5-FU) dose optimization product. Patient sample handling can now be conducted at room temperature, eliminating the need for frozen sample handling. Myriad said that it believes the simplified process should increase physician acceptance and utilization of OnDose.

28 Apr 2010

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

Icagen, Inc. today provided an update on clinical development plans for ICA-105665, the Company's novel drug candidate for the treatment of epilepsy and pain.

28 Apr 2010

ChronSeal multi-center study in Sweden and Norway finalized

The multi-center study in Sweden and Norway with ChronSeal® is now finalized and the data are being analyzed in Sweden and by Kringle in Japan. ChronTech and Kringle have jointly decided that the results will be publicly available on May 27th. At follow-up of the ChronVac-C® -study where patients now have started treatment according to standard-of-care (interferon and ribavirin) all patients (100%) were virus free at treatment week 12 and 5/6 (83%) had less than 50 copies of virus/mL blood already at treatment week four.

28 Apr 2010

FDA issues warning over faulty components in external defibrillators

About 280,000 external defibrillators used worldwide in health care facilities, public places, or in the home may malfunction during attempts to rescue people in sudden cardiac arrest, the U.S. Food and Drug Administration warned today.

28 Apr 2010

Companies providing home care receive large Medicare reimbursements

An analysis of Medicare payments to home health care companies by The Wall Street Journal indicates that some might be taking advantage of the system. According to the analysis, the industry's largest company, Amedisys Inc., "provided many of its patients just enough therapy visits to trigger the extra $2,200 payment.

28 Apr 2010

Study results from US Military Malaria Vaccine Program announced

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that the US Military Malaria Vaccine Program presented results of its study using the Biojector2000 with a recombinant DNA vaccine at two recent conferences. A Cooperative Research and Development Agreement was signed with the Navy in April 2009 to work together on the study.

28 Apr 2010

Tel Aviv University researcher pioneers 3-D occupational therapy for children with disabilities

It was her love of ballet that led her to work with children who have motor disabilities. The retired dancer, now an occupational therapist, is pioneering a new "virtual" method to analyze movement patterns in children ― and more effectively treat those with debilitating motor disorders.

28 Apr 2010

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

Cell Therapeutics, Inc. today announced that the North Central Cancer Treatment Group ("NCCTG") plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast ("mTNBC") cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2. Additionally, the majority of breast cancers that are associated with the susceptibility mutation (BRCA1) are of the triple-negative type.

28 Apr 2010

Head- and neck-cancer patients who continue to smoke during radiation therapy have poorer overall survival

Smokers who don't quit before radiation therapy for throat, mouth and other head and neck cancers fair significantly worse than those who do, research from the UC Davis Cancer Center has found.

28 Apr 2010

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies, a New Zealand-based biotechnology company focused on developing cell based therapeutics, in a Phase II clinical trial to study the safety and effectiveness of transplanting encapsulated insulin-producing cells from pigs as a treatment for type 1 diabetes with significant hypoglycemia unawareness.

28 Apr 2010

SI-BONE to present iFuse MIS procedure at WCMISST 2010

SI-BONE, Inc., a medical device company that is pioneering the use of a minimally invasive surgical device to treat the sacroiliac joint today announced that iFuse initial post-market clinical experience will be presented at upcoming 2010 minimally invasive spine surgery meetings.

28 Apr 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

Ranibizumab eye injections plus laser therapy result in dramatic visual improvement

Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina.

28 Apr 2010

DRCR Network study finds new treatment more effective

A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration.

28 Apr 2010

Therapy News and Research

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

Study examines world-wide use of HSCT

Causes of death in AIDS patients

Volcano to distribute AngioSculpt PTCA Scoring Balloon Catheter in Japan

Transplanted pig cells may bring relief from insulin injections in type I diabetics

Myriad Genetics OnDose collection kit eliminates need for frozen sample handling

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

ChronSeal multi-center study in Sweden and Norway finalized

FDA issues warning over faulty components in external defibrillators

Companies providing home care receive large Medicare reimbursements

Study results from US Military Malaria Vaccine Program announced

Tel Aviv University researcher pioneers 3-D occupational therapy for children with disabilities

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

Head- and neck-cancer patients who continue to smoke during radiation therapy have poorer overall survival

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

SI-BONE to present iFuse MIS procedure at WCMISST 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Ranibizumab eye injections plus laser therapy result in dramatic visual improvement

DRCR Network study finds new treatment more effective

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News